Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary Prevention (PANDORA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00689377
First received: May 29, 2008
Last updated: March 19, 2012
Last verified: March 2012
  Purpose

Non interventional study aimed to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index (ABI) not above 0.90 in subjects with a moderate risk of cardiovascular disease, with no overt cardiovascular diseases nor diabetes mellitus.


Condition
Peripheral Arterial Disease (PAD)
Moderate Risk for Cardiovascular Disease (CVD)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Prevalence of Peripheral Arterial Disease in Subjects With a Moderate CVD Risk, With No Overt Vascular Diseases nOR diAbetes Mellitus

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of lower extremities peripheral arterial disease (PAD), in subjects with a moderate CVD risk, with no overt cardiovascular diseases nor diabetes mellitus [ Time Frame: 1 visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Prevalence of cardiovascular risk factors in subjects with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus [ Time Frame: 1 visit ] [ Designated as safety issue: No ]
  • Cardiovascular risk level and risk factor treatment in the selected population assessed according to the locally adopted risk charts or algorithms [ Time Frame: 1 visit ] [ Designated as safety issue: No ]
  • Determinants (i.e., subject and physician characteristics) for PAD underdiagnosis in the selected population [ Time Frame: 1 visit ] [ Designated as safety issue: No ]

Enrollment: 9000
Study Start Date: May 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus

Criteria

Inclusion Criteria:

  • Male subject aged 45 years or above, or female subject aged 55 years or above (age-related CVD risk factor)
  • At least another of the following risk factor for CVD: cigarette smoking, hypertension, low HDL cholesterol or high LDL cholesterol, family history of premature coronary heart disease, elevated waist circumference
  • Willingness to participate in the survey and complying with the study by signing a written informed consent

Exclusion Criteria:

  • No or 1 risk factor for CVD; symptoms of PAD; diabetes mellitus; coronary heart disease or equivalents
  • No lipid data collected in the last 12 months
  • Serious or unstable medical or psychological conditions that, in the opinion of the Investigator, would compromise the subject's safety or successful participation in the study; unwilling or unable to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00689377

  Show 334 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Raffaele Sabia AstraZeneca S.p.A.
Study Chair: Mario Mangrella AstraZeneca S.p.A
Study Chair: Claudio Cimminiello Unit of Medicine, Vimercate Hospital - Vimercate (MI) - Italy
Study Chair: Claudio Borghi Internal Medicine Dept., di Medicina Interna, Policlinico Universitario Sant'Orsola-Malpighi, Bologna, Italy
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00689377     History of Changes
Other Study ID Numbers: NIS-CEU-DUM-2006/1
Study First Received: May 29, 2008
Last Updated: March 19, 2012
Health Authority: France: Direction Générale de la Santé
Greece: National Organization of Medicines
Italy: Ethics Committee
Netherlands: Medical Ethics Review Committee (METC)
Switzerland: Ethikkommission

Keywords provided by AstraZeneca:
Peripheral Arterial Disease (PAD)
Cardiovascular Disease (CVD)
Atherosclerotic cardiovascular disease
Atherosclerosis
Primary CVD prevention

Additional relevant MeSH terms:
Cardiovascular Diseases
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on July 22, 2014